Article Per Year (5 Year)
p-Index From 2021 - 2026
0.23
P-Index
This Author published in this journals
All Journal Farmaka IDJP (Indonesian Journal of Pharmaceutics)
Amelia, Nisa Ayu
Unknown Affiliation
Biochemistry, Genetics & Molecular Biology Chemistry Health Professions Immunology & microbiology Materials Science & Nanotechnology Medicine & Pharmacology Public Health

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
HUBUNGAN ANTARA INDEKS MASSA TUBUH DENGAN TEKANAN DARAH SOLEH, SOLEH; Listiani, Nita; Maya, Ira; Amelia, Nisa Ayu; Hadad, Nur Diana; El Yahya, Idzni Rusydina; Pardosi, Yessica; Elisabeth, Erlin; Sidharta, Kenny Dwi; Arifa, Irbah; Sinuraya, Rano Kurnia; Destiani, Dika Pramita; Wicaksono, Imam Adi
Farmaka Vol 17, No 3 (2019): Farmaka (Desember)
Publisher : Fakultas Farmasi, Universitas Padjadjaran

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (36.509 KB) | DOI: 10.24198/jf.v17i3.22151

Abstract

ABSTRAK Indeks massa tubuh (IMT) adalah salah satu metode untuk menentukan status gizi seorang individu dengan ditentukan dari hasil pengukuran dari berat badan (kg) dibandingkan terhadap tinggi badan (m2). Nilai IMT yang besar atau kategori overweight dapat meningkatkan risiko berbagai penyakit kardiovaskular, salah satunya hipertensi. Hal ini dikarenakan semakin besar massa tubuh atau indeks massa tubuh seseorang, maka akan semakin banyak juga darah yang akan diperlukan untuk menyalurkan oksigen ke jaringan tubuh, menyebabkan peningkatan tekanan darah. Resiko relatif mengalami hipertensi pada seseorang dengan IMT >25 yaitu 5 kali lebih tinggi dari pada seseorang yang berat memiliki berat badan normal. Tujuan dari penelitian ini adalah untuk mengetahui hubungan Indeks Massa Tubuh (IMT) dengan tekanan darah. Metode yang digunakan adalah analitik observasional dengan analisis korelasi Spearman untuk menentukan korelasinya. Hasil penelitian menunjukkan bahwa adanya korelasi antara IMT dengan tekanan darah dengan nilai CI sebesar 95% serta nilai koefisien korelasi IMT-sistol sebesar 0,356 dan nilai koefisien korelasi IMT-diastol sebesar 0,319. Kata Kunci:  Indeks Massa Tubuh (IMT), Tekanan Darah, Analitik Observasional
 The Efficacy of Favipiravir Therapy in COVID-19 Patients: A Review Article Kurniawansyah, Insan Sunan; Amelia, Nisa Ayu
Indonesian Journal of Pharmaceutics Vol 7, Issue 2, May - August 2025
Publisher : Universitas Padjadjaran (Unpad)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.24198/idjp.v7i2.68959

Abstract

The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19), has resulted in a major global public health crisis. In the absence of a universally approved specific antiviral therapy, several existing antiviral agents have been repurposed, including favipiravir. Favipiravir is a purine nucleoside analog that inhibits RNA-dependent RNA polymerase (RdRp), an essential enzyme for viral RNA replication. This review aims to evaluate the clinical efficacy of favipiravir therapy in patients with COVID-19. A narrative literature review was conducted using databases such as PubMed and Google Scholar, including national and international peer-reviewed journals published between 2019 and 2021. Clinical trials, randomized controlled trials, and observational studies assessing favipiravir in COVID-19 patients were included, while articles lacking accessible full texts or reliable data were excluded. The reviewed studies indicate that favipiravir therapy is associated with improved clinical outcomes, including reduced duration of fever and cough and accelerated viral clearance within 7–14 days of hospitalization, particularly in patients with mild to moderate COVID-19. However, considerable variability in outcomes was observed due to differences in study design, sample size, dosing regimens, comparator therapies, and treatment duration. Overall, favipiravir demonstrates potential as an antiviral therapy for COVID-19; nevertheless, large-scale, well-designed randomized controlled trials are required to definitively confirm its efficacy and safety across different patient populations. 
Co-Authors Arifa, Irbah Dika Pramita Destiani, Dika Pramita El Yahya, Idzni Rusydina Elisabeth, Erlin Hadad, Nur Diana IMAM ADI WICAKSONO, IMAM ADI Insan Sunan Kurniawansyah, Insan Sunan Listiani, Nita MAYA, IRA Pardosi, Yessica RANO KURNIA SINURAYA Sidharta, Kenny Dwi Soleh, Soleh